|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,268.10 INR | +0.86% |
|
-0.19% | +7.39% |
| 06-05 | Lupin Gets US FDA Approval for Ranluspec Interchangeable Biosimilar for Eyesight Ailments | MT |
| 06-04 | Lupin Limited Receives Approval from U.S. FDA for Ranluspec Ranibizumab Injection | CI |
EPS & Dividend: Lupin Limited
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Dividend per Share 2 | 6.5 | 4 | 4 | 8 | 12 | 18 | 13.06 | 12.51 |
| Rate of return | 0.64% | 0.54% | 0.62% | 0.49% | 0.59% | 0.78% | 0.58% | 0.55% |
| EPS 2 | 26.72 | -33.65 | 9.41 | 41.87 | 71.69 | 116.4 | 100.7 | 102.6 |
| Distribution rate | 24.3% | -11.9% | 42.5% | 19.1% | 16.7% | 15.5% | 13% | 12.2% |
| Reference price 2 | 1,020.95 | 746.05 | 647.85 | 1,617.85 | 2,026.50 | 2,268.10 | 2,268.10 | 2,268.10 |
| Nbr of stocks (in thousands) | 453,680 | 454,475 | 454,981 | 455,679 | 456,565 | 457,216 | - | - |
| Announcement Date | 12/05/21 | 18/05/22 | 09/05/23 | 06/05/24 | 14/05/25 | 07/05/26 | - | - |
1INR in Million2INR
Estimates
Past dividends: Lupin Limited
| 25/07/2025 | Ex-dividend date - 12 INR | 05:00 |
| Dividend Yield (Y) | Dividend Yield (Y+1) | P/E (Y) | Price to Book (Y) | EV / Sales (Y) | ||
|---|---|---|---|---|---|---|
 | 0.59% | 0.58% | 20.85x | 4.86x | 3.77x | |
| 0.6% | 0.67% | 33.11x | 19.76x | 12.04x | |
| 2.29% | 2.39% | 24.88x | 6.26x | 5.74x | |
| 3.02% | 3.18% | 27.82x | -827.16x | 6.77x | |
| 3.07% | 3.14% | 17.55x | 6.47x | 4.34x | |
| 2.77% | 2.87% | 53.89x | 6.13x | 5.01x | |
| 1.8% | 1.9% | 23.42x | 5.41x | 4.85x | |
| 3.06% | 3.14% | 20.62x | 6.16x | 5.32x | |
| 4% | 3.84% | 12.56x | 5.5x | 4.71x | |
| 2.89% | 3.05% | 22.73x | 16.95x | 6.08x | |
| Average | 2.41% | 2.48% | 25.74x | -74.97x | 5.86x | |
| Weighted average by Cap. | 2.14% | 2.23% | 28.06x | -83.69x | 7.31x |
Year-on-year evolution of the Yield
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Estimates Revisions
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
Annual Profit -
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition